Comparison of Coagulation Profiles in Oral Contraceptive Pills Users Between 1.5 mg Estradiol/2.5 mg Nomegestrol Acetate (Zoely) and 15 mcg Ethinylestradiol/60 mcg Gestodene (Minidoz): A Randomized Control Trial

The purpose of this study is to compare the effects of Zoely® and Minidoz® on hemostatic profiles

开始日期2016-03-01

申办/合作机构

Mahidol University

NCT01723579 / Withdrawn临床3期

An Open-label, Multi-center Trial to Evaluate the Contraceptive Efficacy, Safety and Acceptability of a Monophasic Combined Oral Contraceptive (COC) Containing 2.5 mg Nomegestrol Acetate (NOMAC) and 1.5 mg Estradiol (E2) in Indian Women. Protocol MK-8175A-017-00

This study will investigate the efficacy and safety of the monophasic
combined oral contraceptive (COC) containing 2.5 mg NOMAC and 1.5 mg E2 in
healthy fertile Indian women.

开始日期2013-07-01

申办/合作机构

Organon & Co.

NCT01709318 / Completed临床2期

A Multicenter, Randomized, Partially-blinded, Phase IIb Dose-finding Study on Ovarian Function, Vaginal Bleeding Pattern, and Pharmacokinetics Associated With the Use of Combined Vaginal Rings Releasing 17β-estradiol Plus Three Different Doses of Either Nomegestrol Acetate or Etonogestrel in Healthy Women Aged 18-35 Years. Protocol MK-8175A/MK-8342B 012

The primary objective of this trial was to identify at least one next generation ring (NGR) that demonstrates inhibition of ovulation (which was considered confirmed if in the subset of participants ovulation was observed in less than 15% of the participants at any time during the 3 treatment cycles of the study) and cycle control that was non-inferior to NuvaRing®, as judged by the incidence of breakthrough bleeding and/or spotting (BTB-S) during Cycle 3. The primary hypothesis was that at least 1 of the 6 NGRs would show inhibition of ovulation and cycle control during Treatment Cycle 3 that is non-inferior to NuvaRing®, as judged by the incidence of BTB-S.

开始日期2012-12-12

申办/合作机构

Organon & Co.

100 项与醋酸诺美孕酮相关的临床结果

登录后查看更多信息

100 项与醋酸诺美孕酮相关的转化医学

登录后查看更多信息

100 项与醋酸诺美孕酮相关的专利（医药）

登录后查看更多信息

308

项与醋酸诺美孕酮相关的文献（医药）

2024-08-01·European Journal of Obstetrics & Gynecology and Reproductive Biology

The use of oral nomegestrol acetate/estradiol in rapid and random start preparation of endometrium before office hysteroscopic polypectomies: A multicenter, prospective, randomized controlled trial

Article

作者: Riemma, Gaetano ; Russo, Giuseppe ; Golia D'Augè, Tullio ; Pecorino, Basilio ; Etrusco, Andrea ; Ferrari, Federico ; Giannini, Andrea ; Chiantera, Vito ; Agrifoglio, Vittorio ; Monti, Marco ; D'Amato, Antonio ; Laganà, Antonio Simone

OBJECTIVETo evaluate the use of oral nomegestrol acetate/estradiol in random start rapid preparation of endometrium before office hysteroscopic polypectomy.STUDY DESIGNMulticenter, prospective, randomized controlled trial.SETTINGUniversity hospitals.PARTICIPANTS80 adult women undergoing office hysteroscopic polypectomy between January 2023 and March 2024 were randomized to intervention (n = 40) or control (n = 40). Exclusion criteria included the presence of endouterine pathology other than endometrial polyps solely.METHODSSubjects in the intervention group were treated with oral nomegestrol acetate/estradiol 1.5 mg/2.5 mg/day started taking the drug from an indefinite time in the menstrual cycle (random start) for 14 days. Subjects in the control group did not receive any pharmaceutical treatment and underwent polypectomy between days 8 and 11 of the menstrual cycle.RESULTSOn the day of the procedure, the difference in pre- and post-office hysteroscopic polypectomy endometrial ultrasound thickness was statistically significant between the two groups, with endometrial thickness in both measurements being thinner for the intervention group (p < 0.001). In the nomegestrol acetate/estradiol-treated group, compared with the control, there was also a statistically significant difference in the physician's assessment of the quality of endometrial preparation (p < 0.001), the quality of visualization of the uterine cavity (p < 0.001), and satisfaction with the performance of the procedure (p < 0.001). Finally, all surgical outcomes analyzed were better in the treatment group.CONCLUSIONTreatment with nomegestrol acetate/estradiol could provide rapid, satisfactory and low-cost preparation of the endometrium before office polypectomy, thus improving surgical performance and woman's compliance.TRIAL REGISTRATIONClinicalTrials.gov NCT06316219.

2024-07-01·The Lancet Regional Health - Europe

Prolonged use of nomegestrol acetate and risk of intracranial meningioma: a population-based cohort study

Article

作者: Nguyen, Pierre ; Hoisnard, Léa ; Zureik, Mahmoud ; Duranteau, Lise ; Froelich, Sébastien ; Coste, Joël ; Weill, Alain ; Passeri, Thibault ; Neumann, Anke ; Roland, Noémie

BackgroundNomegestrol acetate (NOMAC) is a synthetic potent progestogen. This study aimed to assess the risk of intracranial meningioma associated with the prolonged use of NOMAC.MethodsObservational cohort study using SNDS data (France). Women included had ≥ one dispensing of NOMAC between 2007 and 2017 (no dispensing in 2006). Exposure was defined as a cumulative dose >150 mg NOMAC within six months after first dispensing. A control group of women (cumulative dose ≤150 mg) was assembled. The outcome was surgery (resection or decompression) or radiotherapy for one or more intracranial meningioma(s). Poisson models assessed the relative risk (RR) of meningioma.FindingsIn total, 1,060,779 women were included in the cohort (535,115 in the exposed group and 525,664 in the control group). The incidence of meningioma in the two groups was 19.3 and 7.0 per 100,000 person-years, respectively (age-adjusted RRa = 2.9 [2.4-3.7]). The RRa for a cumulative dose of more than 6 g NOMAC was 12.0 [9.9-16.0]. In the event of treatment discontinuation for at least one year, the risk of meningioma was identical to that in the control group (RRa = 1.0 [0.8-1.3]). The location of meningiomas in the anterior and middle part of the skull base was more frequent with exposure to NOMAC.InterpretationWe observed a strong dose-dependent association between prolonged use of NOMAC and the risk of intracranial meningiomas. These results are comparable to those obtained for cyproterone acetate, although the magnitude of the risk is lower. It is now recommended to stop using NOMAC if a meningioma is diagnosed.FundingThe French National Health Insurance Fund (Cnam) and the French National Agency for Medicines and Health Products Safety (ANSM) via the Health Product Epidemiology Scientific Interest Group EPI-PHARE.

2024-04-01·Contraception

Systematic analysis of combined oral contraceptive prescription patterns in psychotropic drug users across twelve European countries

Article

作者: Franke, Christian ; Boehnke, Tanja ; Bauerfeind, Anja ; Heinemann, Klaas ; Kolberg-Liedtke, Cornelia ; Koelkebeck, Katja

OBJECTIVETo investigate prescription patterns of combined oral contraceptives (COC) among psychotropic drug users compared to non-psychotropic drug users in routine clinical practice in Europe.STUDY DESIGNA pooled analysis of three large, prospective, multinational cohort studies including women with a new prescription of COC from 12 European countries. We calculated standardized mean differences (SMD) to investigate whether the status of psychotropic drug use (use/no use) or the psychotropic drug class (psycholeptics/psychoanaleptics) is associated with the healthcare professional's choice of a specific type of COC progestin.RESULTSOur analysis comprised 143,069 non-psychotropic drug users and 2174 psychotropic drug users. Progestins with the highest frequency in the cohorts were levonorgestrel (non-psychotropic drug users: 33.8%; psychotropic drug users: 32.4%), nomegestrol/nomegestrol acetate (non-psychotropic drug users: 19.1%; psychotropic drug users: 26.4%), and drospirenone (non-psychotropic drug users: 15.9%; psychotropic drug users: 14.8%). SMD analysis indicated no substantial differences in COC prescription patterns between the two cohorts. However, we observed association signals for users of the herbal antidepressant St. John's wort in that those individuals more often received a prescription for drospirenone and less frequently for nomegestrol/nomegestrol acetate compared to non-psychotropic drug users.CONCLUSIONSPsychotropic drug user status does not seem to affect healthcare professionals' decisions when prescribing COC. However, limited evidence suggests that the risk for drug interactions might differ by progestin type, and some COC might be more suitable for psychotropic drug users than others. Specific guidelines should be conveyed to healthcare professionals to assist them in contraceptive counseling.IMPLICATIONSWith exception of St. John's wort, our analysis showed no differential prescription behavior of combined oral contraceptives in psychotropic drug users and non-users. However, healthcare professionals should carefully consider psychotropic drug use in contraceptive counseling as it is still unclear whether drug interactions exist when co-administered with certain oral contraceptives.

项与醋酸诺美孕酮相关的新闻（医药）

2022-09-16

·ema

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 September 2022

12 new medicines recommended for approval EMA’s human medicines committee ( CHMP ) recommended 12 medicines for approval at its September 2022 meeting. The CHMP recommended granting a marketing authorisation for Beyfortus (nirsevimab) intended for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV season (when there is a risk of RSV infection in the community). Beyfortus was supported through EMA's PRIority MEdicines (PRIME) scheme, which provides early and enhanced scientific and regulatory support to medicines that have a particular potential to address patients' unmet medical needs. See more information in the news announcement in the grid below. The committee adopted a positive opinion for Enjaymo * (sutimlimab) for the treatment of haemolytic anaemia (breakdown of red blood cells) in adult patients with cold agglutinin disease, a rare autoimmune disorder characterised by the premature destruction of red blood cells. Livtencity * (maribavir) received a positive opinion for the treatment of adults and paediatric patients with cytomegalovirus infection and/or disease that is refractory to one or more prior therapies. Cytomegalovirus is a type of herpes virus that commonly causes infection after a stem cell or an organ transplant. The committee adopted a positive opinion for Melatonin Neurim (melatonin) for the treatment of insomnia, a sleeping disorder affecting more than 10% of the European Union (EU) population. The CHMP gave a positive opinion for Mycapssa * (octreotide) for the treatment of acromegaly, a rare hormonal disorder where the body produces too much growth hormone. This causes body tissues and bones to grow more quickly, leading e.g. to the enlargement of the hands, feet, forehead, jaw or nose. The committee recommended granting a conditional marketing authorisation for Pyrukynd * (mitapivat) for the treatment of an inherited condition called pyruvate kinase deficiency, a rare genetic disorder characterised by the premature destruction of red blood cells. Zynlonta * (loncastuximab tesirine) received a positive opinion from the CHMP . This medicine is intended for the treatment of adult patients with diffuse large B-cell lymphoma and high-grade B-cell lymphoma, two types of cancer that begin in the lymphatic system when abnormal white blood cells grow. The committee adopted a positive opinion for the biosimilar medicine Ximluci (ranibizumab) for the treatment of neovascular age-related macular degeneration, a progressive retinal macular disease, causing gradual vision impairment, mainly in the elderly population. The CHMP recommended granting a marketing authorisation for Teriparatide SUN (teriparatide) for the treatment of osteoporosis in adults. Osteoporosis affects around 22% of women over the age of 50 in the EU. The recommendation followed a hybrid application, which relies in part on the results of pre-clinical tests and clinical trials of an already authorised reference product and in part on new data. The CHMP gave a positive opinion for the generic medicine Sorafenib Accord (sorafenib) for the treatment of hepatocellular carcinoma and renal cell carcinoma, two cancers that start in cells or tissues of the liver and kidney. The committee adopted a positive opinion for the generic medicines Teriflunomide Accord and Teriflunomide Mylan (teriflunomide), indicated for the treatment of multiple sclerosis, a chronic disease affecting the central nervous system. Recommendations on extensions of therapeutic indication for 11 medicines The committee recommended 12 extensions of indication for medicines that are already authorised in the EU: Adtralza , Biktarvy , Brukinsa , Evusheld , Exparel liposomal, Revolade, Skyrizi , Vaxneuvance , Veklury (includes two extensions of indication for two paediatric populations, see the COVID-19 update below), Xalkori and Yescarta . Withdrawals of initial applications The application for marketing authorisation for Exkivity was withdrawn by the respective applicant. This medicine was indicated for the treatment of a certain type of lung cancer. A question-and-answer document on the withdrawal is available in the grid below. The application for marketing authorisation for Sevsury was withdrawn by the respective applicant. This medicine was indicated for the treatment of progressive neuroendocrine tumours. A question-and-answer document on the withdrawal is available in the grid below. Re-examination concluded The CHMP confirmed its recommendation to suspend the marketing authorisations of several generic medicines tested by Synchron Research Services , a contract research organisation (CRO) located in Ahmedabad, India. This concludes the re-examination requested by the marketing authorisation holders for some of the medicines concerned. For more information, see the public health communication in the grid below. COVID-19 update Since the CHMP meeting in July, several recommendations related to COVID-19 vaccines and therapeutics were made. Authorising use of Nuvaxovid as a booster dose for adults who have had Nuvaxovid, an mRNA vaccine or an adenoviral vector vaccine as their primary vaccination. (The recommendation was made on 1 September 2022) Authorising two vaccines adapted to provide broader protection against COVID-19. Comirnaty Original/Omicron BA.1 and Spikevax bivalent Original/Omicron BA.1 are for use in people aged 12 years and above who have received at least primary vaccination against COVID-19. For more information, see the news announcement . (The recommendation was made on 1 September 2022) COVID-19 recommendations adopted during the present meeting of the CHMP : Authorising the adapted bivalent vaccine Comirnaty Original/Omicron BA.4-5 for use in people aged 12 years and above who have received at least a primary course of vaccination against COVID-19. This vaccine is an adapted version of the mRNA COVID-19 vaccine Comirnaty and targets the Omicron subvariants BA.4 and BA.5 in addition to the original strain of SARS-CoV-2. For more information, see the news announcement . Converting the conditional marketing authorisations of the COVID-19 vaccines Comirnaty and Spikevax into standard marketing authorisations . CHMP considered that the additional studies conducted by the companies as part of their post-authorisation obligations have provided ample information on the vaccines’ protection against COVID-19, as well as their quality and safety. For more information, see the news announcement . Approving a new manufacturing site in Dessau-Rosslau, Germany, for COVID-19 Vaccine Valneva . Authorising booster doses of Comirnaty for children from 5 to 11 years of age . Extending the use of COVID-19 therapeutic Evusheld for the treatment of adults and adolescents with COVID-19 who do not require supplemental oxygen. Extending the use of COVID-19 therapeutic Veklury in two paediatric populations: Paediatric patients (of at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen or other non-invasive ventilation at the start of treatment. Paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19. Safety update At its extraordinary meeting, on 2 September 2022, the CHMP endorsed the recommendation of the Pharmacovigilance Risk Assessment Committee ( PRAC ) and recommended that medicines containing high-dose nomegestrol (3.75 – 5 mg) or high-dose chlormadinone (5 – 10 mg) should be used at the lowest effective dose and for the shortest duration possible, and only when other interventions are not appropriate. In addition, low- and high-dose nomegestrol- or chlormadinone-containing medicines must not be used by patients who have, or have had, meningioma. For more information, see the news announcement . Agenda and minutes The agenda of the September 2022 CHMP meeting is published on EMA's website. Minutes of the September 2022 CHMP meeting will be published in the coming weeks. CHMP statistics Key figures from the September 2022 CHMP meeting are represented in the graphic below. *This product was designated as an orphan medicine during its development. Orphan designations are reviewed by EMA's Committee for Orphan Medicinal Products ( COMP ) at the time of approval to determine whether the information available to date allows maintaining the medicine’s orphan status and granting the medicine ten years of market exclusivity . Positive recommendations on new medicines Name of medicine Beyfortus International non-proprietary name (INN) nirsevimab Marketing-authorisation applicant AstraZeneca AB Therapeutic indication Prevention of respiratory syncytial virus lower respiratory tract disease in newborns and infants More information Beyfortus: Pending EC decision News announcement: New medicine to protect babies and infants from respiratory syncytial virus (RSV) infection Name of medicine Enjaymo INN sutimlimab Marketing-authorisation applicant Genzyme Europe BV Therapeutic indication Treatment of haemolytic anaemia in adult patients with cold agglutinin disease More information Enjaymo: Pending EC decision Name of medicine Livtencity INN maribavir Marketing-authorisation applicant Takeda Pharmaceuticals International AG Ireland Branch Therapeutic indication Treatment of cytomegalovirus infection and/or disease that is refractory to one or more prior therapies More information Livtencity: Pending EC decision Name of medicine Melatonin Neurim INN melatonin Marketing-authorisation applicant RAD Neurim Pharmaceuticals EEC SARL Therapeutic indication Treatment of insomnia More information Melatonin Neurim: Pending EC decision Name of medicine Mycapssa INN octreotide Marketing-authorisation applicant Amryt Pharmaceuticals DAC Therapeutic indication Treatment of acromegaly More information Mycapssa: Pending EC decision Name of medicine Pyrukynd INN mitapivat Marketing-authorisation applicant Agios Netherlands B.V. Therapeutic indication Treatment of pyruvate kinase deficiency More information Pyrukynd: Pending EC decision Name of medicine Zynlonta INN loncastuximab tesirine Marketing-authorisation holder ADC Therapeutics (NL) B.V. Therapeutic indication Treatment of adult patients with diffuse large B-cell lymphoma and high-grade B-cell lymphoma More information Zynlonta: Pending EC decision Positive recommendation on new biosimilar medicine Name of medicine Ximluci INN ranibizumab Marketing-authorisation applicant STADA Arzneimittel AG Therapeutic indication Treatment of neovascular age-related macular degeneration More information Ximluci: Pending EC decision Positive recommendation on new hybrid medicine Name of medicine Teriparatide SUN INN teriparatide Marketing-authorisation applicant Sun Pharmaceutical Industries Europe B.V. Therapeutic indication Treatment of osteoporosis in adults More information Teriparatide SUN: Pending EC decision Positive recommendations on new generic medicines Name of medicine Sorafenib Accord INN sorafenib Marketing-authorisation applicant Accord Healthcare S.L.U. Therapeutic indication Treatment of hepatocellular carcinoma and renal cell carcinoma More information Sorafenib Accord: Pending EC decision Name of medicine Teriflunomide Accord INN teriflunomide Marketing-authorisation applicant Accord Healthcare S.L.U. Therapeutic indication Treatment of multiple sclerosis More information Teriflunomide Accord: Pending EC decision Name of medicine Teriflunomide Mylan INN teriflunomide Marketing-authorisation applicant Mylan Pharmaceuticals Limited Therapeutic indication Treatment of multiple sclerosis More information To be published shortly Positive recommendations on extensions of indications Name of medicine Adtralza INN tralokinumab Marketing-authorisation holder LEO Pharma A/S More information Adtralza: Pending EC decision Name of medicine Biktarvy INN bictegravir / emtricitabine / tenofovir alafenamide Marketing-authorisation holder Gilead Sciences Ireland UC More information Biktarvy: Pending EC decision Name of medicine Brukinsa INN zanubrutinib Marketing-authorisation holder BeiGene Ireland Ltd More information Brukinsa: Pending EC decision Name of medicine Evusheld INN tixagevimab / cilgavimab Marketing-authorisation holder AstraZeneca AB More information Evusheld: Pending EC decision Name of medicine Exparel liposomal INN bupivacaine Marketing-authorisation holder Pacira Ireland Limited More information Exparel liposomal: Pending EC decision Name of medicine Revolade INN eltrombopag Marketing-authorisation holder Novartis Europharm Limited More information Revolade: Pending EC decision Name of medicine Skyrizi INN risankizumab Marketing-authorisation holder AbbVie Deutschland GmbH & Co. KG More information Skyrizi: Pending EC decision Name of medicine Vaxneuvance Common name pneumococcal polysaccharide conjugate vaccine (adsorbed) Marketing-authorisation holder Merck Sharp & Dohme B.V. More information Vaxneuvance: Pending EC decision Name of medicine Veklury INN remdesivir Marketing-authorisation holder Gilead Sciences Ireland UC More information Veklury: Pending EC decision Name of medicine Xalkori INN crizotinib Marketing-authorisation holder Pfizer Europe MA EEIG More information Xalkori: Pending EC decision Name of medicine Yescarta INN axicabtagene ciloleucel Marketing-authorisation holder Kite Pharma EU B.V. More information Yescarta: Pending EC decision Withdrawals of initial marketing authorisation applications Name of medicine Exkivity INN mobocertinib Marketing-authorisationapplicant Takeda Pharma A/S More information Exkivity: Withdrawn application Name of medicine Sevsury INN surufatinib Marketing-authorisationapplicant Hutchmed Europe B.V. More information Sevsury: Withdrawn application Outcome of referral re-examination Name of medicine Synchron Research Services More information Synchron Other updates List item Scientific advice and protocol assistance adopted during the CHMP meeting 12-15 September 2022 (PDF/230.36 KB) (new) Adopted First published: 16/09/2022 EMA/CHMP/SAWP/769857/2022

生物类似药疫苗抗体药物偶联物信使RNA

2022-09-02

·ema

New measures to minimise risk of meningioma with medicines containing nomegestrol or chlormadinone

EMA’s human medicines committee ( CHMP ) has endorsed the recommendation of the Pharmacovigilance Risk Assessment Committee ( PRAC ), which concluded that the benefits of medicines containing nomegestrol or chlormadinone outweigh the risks, provided new measures are taken to minimise the risk of meningioma . A meningioma is a tumour of the membranes covering the brain and spinal cord. It is usually benign and is not considered to be a cancer, but due to their location in and around the brain and spinal cord meningiomas can in rare cases cause serious problems. The CHMP has recommended that medicines containing high-dose nomegestrol (3.75 – 5 mg) or high-dose chlormadinone (5 – 10 mg) should be used at the lowest effective dose and for the shortest duration possible, and only when other interventions are not appropriate. In addition, low- and high-dose nomegestrol- or chlormadinone-containing medicines must not be used by patients who have, or have had, meningioma. As well as restricting the use of the high-dose medicines, the CHMP has recommended that patients should be monitored for symptoms of meningioma, which can include change in vision, hearing loss or ringing in the ears, loss of smell, headaches, memory loss, seizures and weakness in arms or legs. If a patient is diagnosed with meningioma, treatment with these medicines must be permanently stopped. The product information for the high-dose medicines will also be updated to include meningioma as a rare side effect. The recommendations follow a review by the PRAC of available data, including post-marketing safety data and results from two recent epidemiological studies. 1’2 These data showed that the risk of meningioma increases with increasing dose and duration of treatment. The CHMP endorsed the PRAC ’s assessment of this risk. The CHMP opinion has been sent to the European Commission, which will issue a legally binding decision valid across the EU. Information for patients Meningiomas have been reported with the use of nomegestrol- or chlormadinone-containing medicines. This risk, which is very low, is increased when the medicines are used at high doses (3.75 - 5 mg for nomegestrol and 5 - 10 mg for chlormadinone) and for prolonged periods of time. EMA is therefore recommending that these medicines should only be used at the lowest effective dose and for the shortest duration possible. Higher doses (3.75 – 5 mg nomegestrol and 5 - 10 mg chlormadinone) should only be considered if other interventions are not possible. You should not use or be prescribed nomegestrol- or chlormadinone-containing medicines if you have a meningioma or have had one in the past. Contact your doctor immediately if you experience a change in vision (seeing double or blurriness), hearing loss or ringing in the ears, loss of smell, headaches that worsen with time, memory loss, seizures and weakness in your arms or legs. If you are diagnosed with a meningioma while using a nomegestrol- or chlormadinone-containing medicine, your doctor will stop your treatment with the medicine. The risk of meningioma may decrease after you stop treatment with a nomegestrol- or chlormadinone-containing medicine. Information for healthcare professionals Meningiomas (single and multiple) have been reported with the use of nomegestrol- or chlormadinone-containing medicines, particularly at high doses and for prolonged time. The risk increases with increasing cumulative doses. The use of these medicines at high doses should be restricted to situations where other interventions are considered inappropriate, and they should be used at the lowest effective dose and for the shortest duration. Nomegestrol- or chlormadinone-containing medicines are contraindicated in patients with meningioma or a history of meningioma. Patients should be monitored for signs and symptoms of meningiomas in line with clinical practice. If a patient is diagnosed with meningioma, treatment with these medicines should be permanently stopped. Available evidence suggests that the risk of meningioma decreases after treatment discontinuation of the nomegestrol- or chlormadinone-containing medicine. A direct healthcare professional communication (DHPC) will be sent in due course to healthcare professionals prescribing, dispensing or administering the medicine. The DHPC will also be published on a dedicated page on the EMA website. More about the medicine Medicines containing nomegestrol acetate or chlormadinone acetate are available as tablets to be taken by mouth. They are available on their own or in combination with oestrogens to treat gynaecological disorders such as amenorrhoea (absence of menstrual periods) and other menstrual disorders, uterine bleeding, endometriosis (a condition in which tissue similar to the lining of the womb grows elsewhere in the body), breast tenderness, and as hormone replacement therapy or contraceptives (birth control). The medicines are marketed under several trade names including Belara, Lutenyl, Luteran, Naemis and Zoely and as generic medicines . With the exception of Zoely (nomegestrol acetate/estradiol), which is centrally authorised, all medicines reviewed during this procedure have been authorised via national procedures. Warnings about the risk of meningioma are already included in the product information for some of them, although the wording may differ across EU Member States. The CHMP recommendation will lead to alignment of the product information for these medicines across the EU. More about the procedure The review of products containing nomegestrol or chlormadinone was initiated at the request of France, under Article 31 of Directive 2001/83/EC . The review was first carried out by the PRAC , the Committee responsible for the evaluation of safety issues for human medicines, which made a set of recommendations. The PRAC recommendations were sent to the CHMP , responsible for questions concerning medicines for human use, which adopted the Agency’s opinion. The CHMP ’s opinion will now be forwarded to the European Commission, which will issue a final legally binding decision applicable in all EU Member States in due course. 1 Nguyen P, Hoisnard L, Neumann A, Zureik M, Weill A. Utilisation prolongée de l’acétate de chlormadinone et risque de méningiome intracrânien: une étude de cohorte à partir des données du SND. EPI-PHARE , 2021. 2 Nguyen P, Hoisnard L, Neumann A, Zureik M, Weill A. Utilisation prolongée de l’acétate de nomégestrol et risque de méningiome intracrânien: une étude de cohorte à partir des données du SNDS. EPI-PHARE , 2021.

100 项与醋酸诺美孕酮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D08281	醋酸诺美孕酮	G03DB04	DB13981

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
月经过多	摩纳哥	Theramex SpA	1999-12-14
更年期综合症	委内瑞拉	Theramex SpA	1999-12-07
内分泌系统疾病	-	-	-
月经紊乱	-	-	-

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
抑制排卵	临床2期	-	Theramex SpA	1997-02-01
乳腺癌	临床2期	法国	Theramex SpA	-
更年期综合症	临床2期	美国	Theramex SpA	-
月经过多	临床2期	美国	Theramex SpA	-
怀孕	临床2期	法国	Theramex SpA	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01709318 (P06109 \| MK-8175A/MK-8342B-012, CTgov)	临床2期	出血 \| 避孕	666	Estradiol (E2)+Nomegestrol acetate (NOMAC) (Nomegestrol Acetate-17β-Estradiol (NOMAC-E2) 500/300 μg/Day)	糧顧獵網鏇顧艱鏇積積(壓選鬱構繭窪鬱鏇鹹積) = 鬱膚廠積製鬱窪憲蓋鹹選觸簾獵製範醖餘廠顧 (簾鹽積衊膚窪鬱鏇廠鹹, 夢鹽餘鑰顧糧顧鏇顧壓 ~ 蓋餘鹽糧夢獵製鬱膚選) 更多	-	2019-12-05
				Estradiol (E2)+Nomegestrol acetate (NOMAC) (Nomegestrol Acetate-17β-Estradiol (NOMAC-E2) 700/300 μg/Day)	糧顧獵網鏇顧艱鏇積積(壓選鬱構繭窪鬱鏇鹹積) = 蓋鏇糧蓋餘膚構憲壓製選觸簾獵製範醖餘廠顧 (簾鹽積衊膚窪鬱鏇廠鹹, 憲繭顧艱艱鑰選夢範夢 ~ 艱簾遞鑰餘鏇願遞願餘) 更多